Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Tilray Brands (TLRY) A 'Buy' After Q1 Earnings Announcement?
Cannabis company Tilray Brands (TLRY - Free Report) reported fiscal Q1 results earlier this month. Tilray, a Zacks Rank #3 (Hold), plunged amid the worse-than-expected results. But with a potential rescheduling of marijuana at the federal level, is TLRY a buy?
During the first week of October, TLRY reported a wider-than-expected Q1 loss of -$0.08/share. The figure missed the Zacks Consensus Estimate of -$0.06/share by 33%. Revenues for the quarter of $153.21 million also missed estimates by -1.59%. TLRY has exceeded earnings estimates just twice in the past four quarters.
President Biden recently announced a pardon for all prior marijuana simple offenses, while simultaneously initiating an official review of how marijuana is scheduled under federal law. The process could pave the way for a bright future for the cannabis industry. Still, Tilray shares remain volatile despite the favorable industry outlook and have fallen over 50% this year.